South China Morning Post
์ค๋
๊ฒฝ์
Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
Akeso, whose drug ivonescimab was hailed as biotechโs โDeepSeek momentโ amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their target prices upwards. The drugโs phase three trial found that ivonescimab reduced the risk of death...